Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

2000195 citationsJournal Article

Authors

Jameela Al-Salman · Easton Hospital

Heider Arjomand · Easton Hospital

David G. Kemp · Easton Hospital

Manoj Mittal · Easton Hospital

Abstract

Rosiglitazone may be associated with hepatocellular injury. We believe that patients receiving rosiglitazone should have liver enzyme levels monitored earlier and more frequently than initially recommended.

Topics & Keywords

Peroxisome Proliferator-Activated Receptors Drug-Induced Hepatotoxicity and Protection Metabolism and Genetic Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 132, Issue 2, pp. 121-124

DOI: 10.7326/0003-4819-132-2-200001180-00006

Field-Weighted Citation Impact: 12.43